Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma-Reference-Cited by-同舟云学术

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

Published:2017-01-01 Issue:1 Volume:3 Page:28
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Munshi Nikhil C.¹,Avet-Loiseau Herve²,Rawstron Andy C.³,Owen Roger G.³,Child J. Anthony⁴,Thakurta Anjan⁵,Sherrington Paul⁶,Samur Mehmet Kemal¹,Georgieva Anna⁷,Anderson Kenneth C.¹,Gregory Walter M.⁴

Affiliation:

1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

2. Unit for Genomics in Myeloma, Institut Universitaire du Cancer, Toulouse, France

3. St James's University Hospital, Leeds, United Kingdom

4. University of Leeds, Leeds, United Kingdom

5. Celgene Corporation, Summit, New Jersey

6. Celgene International, Boudry, Switzerland

7. Excerpta Medica, Amsterdam, the Netherlands

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 410 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

2. A roadmap towards improving outcomes in multiple myeloma;Blood Cancer Journal;2024-08-12

3. Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies;Hematological Oncology;2024-08-03

4. Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma;Leukemia;2024-08-02

5. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma;Blood;2024-07-25